Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
5.81
+0.07 (1.22%)
At close: Nov 6, 2026, 4:00 PM EST
5.88
+0.07 (1.12%)
After-hours: Nov 6, 2026, 7:30 PM EST
Lifeward Revenue
Lifeward had revenue of $6.62M in the quarter ending June 30, 2026, with 15.71% growth. This brings the company's total for the last twelve months to $21.82M, down -10.68% year-over-year. In the year 2025, Lifeward had annual revenue of $22.03M, down -14.14%. That makes Lifeward the 33,321st largest company in the world by revenue and 4,364th in the United States.
Revenue (ttm)
$21.82M
Revenue Growth
-10.68%
P/S Ratio
0.75
Revenue / Employee
$269,407
Employees
81
Market Cap
16.45M
Revenue by Geography
- United States 13.24M 60.1%
- Germany 4.01M 18.2%
- Europe (Excl. Germany) 2.91M 13.2%
- Rest of The World 1.42M 6.4%
- Asia-Pacific 460.00K 2.1%
Fiscal year ended Dec 31, 2025 See the full Lifeward breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.03M | -3.63M | -14.14% |
| Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | 4.87M | -1.67M | -25.55% |
| Dec 31, 2018 | 6.55M | -1.21M | -15.58% |
| Dec 31, 2017 | 7.75M | 1.88M | 32.10% |
| Dec 31, 2016 | 5.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 394.53M |
| CVRx, Inc. | 60.33M |
| IRIDEX | 51.57M |
| SANUWAVE Health | 44.02M |
| Cytosorbents | 37.22M |
| Nano-X Imaging | 15.63M |
| Pulsenmore | 14.13M |
| Picard Medical | 6.30M |
LFWD News
- 25 days ago - Lifeward’s ReWalk exoskeleton shows sustained long-term home use in study - TheFly
- 25 days ago - Lifeward's ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study - GlobeNewsWire
- 6 weeks ago - Lifeward Proxy statement: Proxy filing - Filings
- 7 weeks ago - Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain - GlobeNewsWire
- 7 weeks ago - Lifeward Proxy statement: Proxy filing - Filings
- 2 months ago - Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy - GlobeNewsWire
- 2 months ago - Lifeward Slides: Investor presentation - Filings
- 2 months ago - Lifeward CEO Mark Grant to depart, Josh Hexter named interim CEO - TheFly